中国临床药理学杂志2018，Vol.34Issue(7)：802-804,3.DOI:10.13699/j.cnki.1001-6821.2018.07.020
重组人血管内皮抑制素注射液联合顺铂注射液治疗恶性胸腔积液的临床研究
Clinical trial of recombinant human endostatin injection combined with cisplatin injection in the treatment of malignant pleural effusion
摘要
Abstract
Objective To observe the clinical efficacy and safety of recombinant human endostatin injection combined with cisplatin injection in the treatment of malignant pleural effusion.Methods Sixty patients with malignant pleural effusion were randomly divided into control and treatment group with 30 cases per group.Control group was given 60 mg per time,twice a week,thoracic perfusion.Treatment group was given recombinant human endostatin 45 mg per time,twice a week,thoracic perfusion,on the basis of control group.Two groups were treated for 3 months.The dose of cisplatin is not more than 120 mg per month,and the disappearance of hydrothorax is stopped.The clinical efficacy and adverse drug reactions were compared between two groups.Results After treatment,the disease control rates of treatment and control groups were 80.00％ (24 cases / 30 cases) and 60.00％ (18 cases / 30 cases) with significant difference (P ＜ 0.05).The adverse drug reactions in two groups were gastrointestinal reactions,fever,fatigue,leukopenia,thrombocytopenia,liver and kidney function damage,and their incidences of adverse drug reactions had no statistically significant difference (all P ＞0.05).Conclusion Recombinant human endostatin injection combined with cisplatin injection has a definitive clinical efficacy in the treatment of malignant pleural effusion,without increasing the incidence of adverse drug reactions.关键词
重组人血管内皮抑制素注射液/顺铂注射液/恶性胸腔积液/安全性Key words
recombinant human endostatin injection/cisplatin injection/malignant pleural effusion/safety分类
医药卫生引用本文复制引用
宋文灿,鲍瑜,钱江,朱立建,操思源,陶正平..重组人血管内皮抑制素注射液联合顺铂注射液治疗恶性胸腔积液的临床研究[J].中国临床药理学杂志,2018,34(7):802-804,3.基金项目
中华国际医学交流基金会资助项目(Z-2014-06-16347,Z-2014-06-16348) （Z-2014-06-16347,Z-2014-06-16348）
